Streetwise Expert Interviews

Grant Zeng

Build Biotech Wealth on Solid Platforms: Grant Zeng

Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination. (4/17/14) More >


Scott Power

Four Hidden Australian Life Sciences Growth Stocks Revealed: Scott Power

To find undiscovered stories, investors must venture into unfamiliar territory. In this interview with The Life Sciences Report, we go halfway around the world to speak with Scott Power of Morgans Financial Ltd. about companies under coverage in Australia. Power helps investors get comfortable with the idea of putting money into newfound names, and unveils four strong ideas that could invigorate adventuresome portfolios and investors hungering for excitement. (4/17/14) More >


Read more Streetwise interviews. . .

including Don't Miss the Boat on Big Biotech Catalysts: Keith Markey (4/10/14) More >


Read more Streetwise interviews. . .

including Hang On, Folks—It's Going to Be a Bumpy Ride: 2014 Biotech Watchlist Update (4/10/14) More >

Newsletter Briefs

"DMPI's VAL-083 is a first-in-class small-molecule chemotherapeutic." (4/17/14) DelMar Pharmaceuticals Inc. - The Life Sciences Report Interview with Grant Zeng More >

"SNGX has a very diversified pipeline under development; its Phase 2 trial for SGX924 is going very well." (4/17/14) Soligenix Inc. - The Life Sciences Report Interview with Grant Zeng More >

"There is great potential for NEO to grow in the future." (4/17/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More >

"RXII has some very important valuation-driving events in progress." (4/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Keith Markey More >

"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More >

"ATHX's MultiStem has the potential to completely change existing treatment paradigms." (4/2/14) Athersys Inc. - Jason Kolbert, Maxim Group More >

"Our price target on DMPI represents 294% upside potential." (3/31/14) DelMar Pharmaceuticals Inc. - SeeThruEquity More >

"We believe AMBS' MANF molecule is one of the jewels in the field." (3/26/14) Amarantus BioScience Holdings Inc. - The Life Sciences Report Interview with David Lowe More >

Expert Analysis

"CTH has huge upside, a clear exit strategy and a drug that works." (4/16/14) Cynapsus Therapeutics Inc. - Jason Napodano, Seeking Alpha More >

"NBS' acquisition of California Stem Cell expands its development pipeline of cell therapy products." (4/14/14) NeoStem Inc. - Henry McCusker, Scimitar Equity LLC More >

"CGIX launched a new test to detect mutations in the CALR gene." (4/14/14) Cancer Genetics Inc. - Jerry Isaacson, LifeSci Advisors More >

"The American Heart Journal reported that CYTX's trial showed the procedure was safe, feasible and showed indications of a favorable benefit-to-risk profile." (4/14/14) Cytori Therapeutics Inc. - Henry McCusker, Scimitar Equity LLC More >

"VRS closed a private placement for gross proceeds of $481K." (4/10/14) Verisante Technology Inc. - Brian Marckx, Zacks Small-Cap Research More >

"We are initiating coverage on TBUFF with a Speculative Buy rating." (4/9/14) Tribute Pharmaceuticals Canada Inc. - André Uddin, Mackie Research Capital More >

"BDSI's robust presence at ASAM should raise awareness of Bunavail." (4/7/14) BioDelivery Sciences International Inc. - Charles Duncan, Piper Jaffray & Co. More >

"CTH's recent $25M financing should fund clinical trials for AP-130277." (4/15/14) Cynapsus Therapeutics Inc. - Jerry Isaacson, LifeSci Advisors More >